214 related articles for article (PubMed ID: 21289271)
1. Humanizing animal models: a key to autoimmune diabetes treatment.
Bresson D; von Herrath M
Sci Transl Med; 2011 Feb; 3(68):68ps4. PubMed ID: 21289271
[TBL] [Abstract][Full Text] [Related]
2. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.
Kuhn C; You S; Valette F; Hale G; van Endert P; Bach JF; Waldmann H; Chatenoud L
Sci Transl Med; 2011 Feb; 3(68):68ra10. PubMed ID: 21289272
[TBL] [Abstract][Full Text] [Related]
3. Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain.
Kuhn C; Rezende RM; da Cunha AP; Valette F; Quintana FJ; Chatenoud L; Weiner HL
J Autoimmun; 2017 Jan; 76():115-122. PubMed ID: 27745778
[TBL] [Abstract][Full Text] [Related]
4. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
5. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.
Bisikirska BC; Herold KC
Ann N Y Acad Sci; 2004 Dec; 1037():1-9. PubMed ID: 15699486
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 1 diabetes with anti-CD3 monoclonal antibody.
Glandt M; Hagopian W; Herold KC
Rev Endocr Metab Disord; 2003 Dec; 4(4):361-8. PubMed ID: 14618021
[No Abstract] [Full Text] [Related]
7. A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.
Gill RG; Pagni PP; Kupfer T; Wasserfall CH; Deng S; Posgai A; Manenkova Y; Bel Hani A; Straub L; Bernstein P; Atkinson MA; Herold KC; von Herrath M; Staeva T; Ehlers MR; Nepom GT
Diabetes; 2016 May; 65(5):1310-6. PubMed ID: 26718498
[TBL] [Abstract][Full Text] [Related]
8. Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.
Maurice Morillon Y; Martin A; Gojanovich G; Wang B; Tisch R
Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):239-50. PubMed ID: 25790749
[TBL] [Abstract][Full Text] [Related]
9. Reversal of New Onset Type 1 Diabetes by Oral
Mbongue JC; Rawson J; Garcia PA; Gonzalez N; Cobb J; Kandeel F; Ferreri K; Husseiny MI
Front Immunol; 2019; 10():320. PubMed ID: 30863412
[TBL] [Abstract][Full Text] [Related]
10. [Prevent and cure insulin-dependent diabetes].
Bach JF
Pathol Biol (Paris); 2003 Apr; 51(3):151-5. PubMed ID: 12781796
[TBL] [Abstract][Full Text] [Related]
11. The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.
Sarikonda G; Sachithanantham S; Miller JF; Pagni PP; Coppieters KT; von Herrath M
J Autoimmun; 2015 May; 59():61-6. PubMed ID: 25772283
[TBL] [Abstract][Full Text] [Related]
12. Otelixizumab in the treatment of type 1 diabetes mellitus.
Sprangers B; Van der Schueren B; Gillard P; Mathieu C
Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
Ilan Y; Shailubhai K; Sanyal A
Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
[TBL] [Abstract][Full Text] [Related]
14. Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors.
Begum S; Chen W; Herold KC; Papaioannou VE
Endocrinology; 2009 Oct; 150(10):4512-20. PubMed ID: 19589867
[TBL] [Abstract][Full Text] [Related]
15. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.
Waldron-Lynch F; von Herrath M; Herold KC
Novartis Found Symp; 2008; 292():146-55; discussion 155-8, 202-3. PubMed ID: 19203097
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
Gaglia J; Kissler S
Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
Rydén AK; Perdue NR; Pagni PP; Gibson CB; Ratliff SS; Kirk RK; Friesen TJ; Haase C; Coppieters K; von Herrath MG; Boursalian TE
J Autoimmun; 2017 Nov; 84():65-74. PubMed ID: 28711285
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
[TBL] [Abstract][Full Text] [Related]
19. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
Chatenoud L
Nat Rev Endocrinol; 2010 Mar; 6(3):149-57. PubMed ID: 20173776
[TBL] [Abstract][Full Text] [Related]
20. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.
Mamchak AA; Manenkova Y; Leconet W; Zheng Y; Chan JR; Stokes CL; Shoda LK; von Herrath M; Bresson D
Diabetes; 2012 Jun; 61(6):1490-9. PubMed ID: 22362174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
